Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like Recent, dramatic shifts in global health funding include cuts to US and UK foreign aid. This has had a cascade of devasting consequences on treatment and prevention programmes, including for HIV and TB across the globe. Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like.
About the speaker:
Mitchell Warren has spent nearly 30 years devoted to expanding access to HIV prevention, working with a wide range of activists and advocates, researchers and scientists, product developers and deliverers, policy makers, community advisory boards and the media from across the globe. This has often been as a translator, helping these often-diverse groups with diverse points of view understand each other better.
Since 2004, Mitchell has been the Executive Director of AVAC, an international non-governmental organization that works to accelerate the ethical development and global delivery of HIV prevention options as part of a comprehensive and integrated pathway to global health equity. Through communications, education, policy analysis, advocacy and a network of global collaborations, it mobilizes and supports efforts to deliver proven HIV prevention tools for immediate impact, demonstrates and rolls out new HIV prevention options, and develops long-term solutions needed to end the epidemic.
All content for Translational Health Sciences is the property of Oxford University and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like Recent, dramatic shifts in global health funding include cuts to US and UK foreign aid. This has had a cascade of devasting consequences on treatment and prevention programmes, including for HIV and TB across the globe. Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like.
About the speaker:
Mitchell Warren has spent nearly 30 years devoted to expanding access to HIV prevention, working with a wide range of activists and advocates, researchers and scientists, product developers and deliverers, policy makers, community advisory boards and the media from across the globe. This has often been as a translator, helping these often-diverse groups with diverse points of view understand each other better.
Since 2004, Mitchell has been the Executive Director of AVAC, an international non-governmental organization that works to accelerate the ethical development and global delivery of HIV prevention options as part of a comprehensive and integrated pathway to global health equity. Through communications, education, policy analysis, advocacy and a network of global collaborations, it mobilizes and supports efforts to deliver proven HIV prevention tools for immediate impact, demonstrates and rolls out new HIV prevention options, and develops long-term solutions needed to end the epidemic.
This lecture will provide a brief journey into the future, providing projections for how our lives will change as technological innovations continue to accelerat In an era marked by unprecedented technological advancements, our world is undergoing a profound transformation that challenges the
very essence of what it means to be human. From the rise of artificial intelligence, to the widespread use of robotics, to advancements in
biotech, to the omnipresence of smartphones, the impact of technology on our lives is undeniable.
Technology has revolutionized how we communicate, work, learn, receive medical care, and perceive reality. As we stand at the
intersection of innovation and human existence, it is imperative to explore the multifaceted ways in which technology is reshaping our
society, raising profound questions about ethics, privacy, and the essence of humanity.
This lecture will provide a brief journey into the future, providing projections for how our lives will change as technological innovations
continue to accelerate. We will examine how we should think about the future as we strive to create a better world. And we will explore
how technology is impacting all areas of human life and how we can leverage behavioural science and human-centred design to ensure that
our growing reliance on technology does not eclipse the fundamental importance of human connections.
Dr. Scott Clarke is Senior Managing Partner and Global Practice Leader for Digital Transformation & Innovation at Infosys Consulting. As a
behavioural economist, Scott has dedicated his career to helping organizations grow and innovate by understanding the ramifications of
sociological and technology change and how this affects relationships with their customers and employees. His current work investigates
how digital technologies are changing the world, and what types of organizations are best able to lead this change rather than being
disrupted by it.
Over a 30-year consulting career, Dr Clarke is proud to have partnered with a variety of leading organizations on their digital transformation
journeys including Unilever, Nestle, Philips, Burberry, Merck, T-Mobile, Gilead Sciences, Chevron, Johnson & Johnson, Ford Motor Company,
and Sony Electronics. Prior to joining Infosys Consulting, he led global management consulting practices for several other professional
services organizations including PwC, IBM, Capgemini and Cognizant.
Dr Clarke holds a DPhil in Behavioural Economics from the University of Strathclyde and a BA (Hons) in Economics and Political Science from
Queen’s University (Canada). He is formerly Senior Lecturer in Behavioural Economics at Queen Mary University of London. His academic
work focuses on the relationship between humanity and technology, and how technology advancements including AI, robotics and biotech
expand humanity’s horizons and redefine what it means to be human.
Translational Health Sciences
Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like Recent, dramatic shifts in global health funding include cuts to US and UK foreign aid. This has had a cascade of devasting consequences on treatment and prevention programmes, including for HIV and TB across the globe. Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like.
About the speaker:
Mitchell Warren has spent nearly 30 years devoted to expanding access to HIV prevention, working with a wide range of activists and advocates, researchers and scientists, product developers and deliverers, policy makers, community advisory boards and the media from across the globe. This has often been as a translator, helping these often-diverse groups with diverse points of view understand each other better.
Since 2004, Mitchell has been the Executive Director of AVAC, an international non-governmental organization that works to accelerate the ethical development and global delivery of HIV prevention options as part of a comprehensive and integrated pathway to global health equity. Through communications, education, policy analysis, advocacy and a network of global collaborations, it mobilizes and supports efforts to deliver proven HIV prevention tools for immediate impact, demonstrates and rolls out new HIV prevention options, and develops long-term solutions needed to end the epidemic.
